Home › Funds › Ally Bridge Group (NY) LLC › VRDN
Ally Bridge Group (NY) LLC position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Ally Bridge Group (NY) LLC reported holding 302,449 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$4.2M, representing 5.51% of its reported portfolio and ranking #8 among its reported holdings. Ally Bridge Group (NY) LLC first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ally Bridge Group (NY) LLC's VRDN position evolved
Ally Bridge Group (NY) LLC first disclosed a stake in VRDN in Q3 2026 at 302,449 shares (US$4.2M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 302.45K | $4.15M | New |
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in VRDN — the largest reported positions include Paradigm Biocapital Advisors LP (US$227.1M), Bellevue Group AG (US$146.4M), Kynam Capital Management, LP (US$126.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Paradigm Biocapital Advisors LP 12.41M sh · $227.08M · Q3 2026
- Bellevue Group AG 7.11M sh · $146.38M · Q3 2026
- Kynam Capital Management, LP 6.15M sh · $126.59M · Q3 2026
- Fairmount Funds Management LLC 5.09M sh · $104.82M · Q3 2026
- RTW INVESTMENTS, LP 4.98M sh · $102.03M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 5.96M sh · $81.79M · Q3 2026
- Novo Holdings A/S 4.87M sh · $78.92M · Q3 2026
- Venrock Adviser, LLC 3.26M sh · $67.08M · Q3 2026
- Deep Track Capital, LP 3.83M sh · $64.34M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 4.50M sh · $61.83M · Q3 2026
- Caligan Partners LP 3.08M sh · $57.34M · Q3 2026
- Context Capital Management, LLC 49.00M sh · $56.47M · Q3 2026
More on Ally Bridge Group (NY) LLC
FAQ
How long has Ally Bridge Group (NY) LLC held VRDN?
Ally Bridge Group (NY) LLC has disclosed VRDN holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Ally Bridge Group (NY) LLC's current position in VRDN?
As of Q3 2026, Ally Bridge Group (NY) LLC holds 302.45K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $4.15M, representing 5.51% of its reported portfolio and ranking #8.
Has Ally Bridge Group (NY) LLC been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Ally Bridge Group (NY) LLC newly opened its position in VRDN.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Paradigm Biocapital Advisors LP, Bellevue Group AG, Kynam Capital Management, LP, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.